$HCWB News

HCW Biologics Regains Nasdaq Compliance After Announcing 1-For-6 Reverse Stock Split, Effective June 30

HCW Biologics Announces 1-For-6 Reverse Stock Split, Effective June 30

Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss

HCW Biologics Says Preliminary Human Data For The First Two Dose Cohorts From Its Dose-escalating Phase 1 Trial Of HCW9302 For Alopecia Areata Shows Clinical Response After Single Dose Administration

HCW Biologics Files Prospectus For Offering 5.69M Common Shares

Maxim Group Maintains Buy on HCW Biologics, Raises Price Target to $5

HCW Biologics Exercises Options To Regain Full Ex Vivo Rights HCW9206, HCW9201 From Wugen

Why Is HCW Biologics Stock Surging On Friday?

Why HCW Biologics Stock Is Surging On Thursday?

HCW Biologics Prices Private Placement Of 2.84M Units At $1.405 Each

Why HCW Biologics Stock Is Falling On Tuesday?

What's Going On With HCW Biologics Stock Monday?

Why Is HCW Biologics Stock Gaining Today?

HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session

HCW Biologics Q1 EPS $0.37 Beats $(0.44) Estimate, Sales $6.543M Up From $5.065K YoY

HCW Biologics Announces Its HCW11-040 Pembrolizumab-based Fusion Immunotherapeutic Discovered To Prevent Bronchopulmonary Dysplasia During IND-Enabling Trials

HCW Biologics shares are trading lower after the company reported a year-over-year decrease in Q4 sales results.

HCW Biologics shares are trading lower after the company reported a year-over-year decrease in Q4 sales results.

HCW Biologics Q4 EPS $(1.02) Up From $(3.19) YoY, Sales $27.010K Down From $394.804K YoY

HCW Biologics shares are trading lower after the company announced a $7 million licensing deal for HCW11-006 with China partner Trimmune, including $3.5 million cash. Also, the company announced that a Phase 1 clinical study is expected in H1 2027.